Investor presentation Full year 2019 55 pports efforts to close the unched xenda® ase 3 tide Obesity ase 2 M833 ase 1 Y 1875 agonist o-agonist GDF15 +AM833 Addressing the gap between today’s medication and bariatric surgery 5-10% % Obesity pipeline 0 priorities Today’s available medication 5 (3-9% after 1 year)1 Increase weight loss towards 10-15% 1150 -30% 15-30% I1n5vestigate product combinations 20 Gap Provide data applicable for in25dividualised treatment 30 Bariatric surgery (12-45% after 3 years)2 Weight loss over time
Download PDF file